# Epsilen Bio S.r.l

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epsilen-bio-s-r-l

- Industry: Biotechnology
- Headquarters: Italy
- Website: www.epsilenbio.com
- Total disclosed funding: $2.8M
- Latest round: Seed (Nov 24, 2020)
- Investors on record: 1

## About

Based in Milano, Italy, and founded in 2019, Epsilen Bio S.r.l, a wholly-owned subsidiary of Chroma Medicine, Inc., operates as a biotechnology company. Angelo Lombardo and Luigi Naldini are the founders of Epsilen Bio. Julia Berretta is the CEO of the company as of 2021. In November 2021, Chroma Medicine, Inc., acquired Epsilen Bio S.r.l. The financial terms of the deal were not disclosed.

The firm specializes in epigenetic editing, which is the process of changing the behavior of genes without altering their DNA. Through permanent and long-lasting epigenetic silencing of genes implicated in pathogenic processes, the business is developing transformational medicines for people suffering from underserved medical illnesses.

Following the acquisition of Chroma Medicine, Inc., the company will continue to operate as a wholly-owned subsidiary of Chroma and further develop the epigenetic silencing technology with the group of Epigenetic Regulation and Targeted Genome Editing.

## Funding rounds

- Seed, Nov 24, 2020, $2.8M — Sofinnova Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed